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Influenza A viruses are a major cause of mortality.
Given the potential for future lethal pandemics, effec-
tive drugs are needed for the treatment of severe
influenza such as that caused by H5N1 viruses. Using
mediator lipidomics and bioactive lipid screen, we
report that the omega-3 polyunsaturated fatty acid
(PUFA)-derived lipid mediator protectin D1 (PD1)
markedly attenuated influenza virus replication via
RNA export machinery. Production of PD1 was sup-
pressed during severe influenza and PD1 levels
inversely correlated with the pathogenicity of H5N1
viruses. Suppression of PD1was geneticallymapped
to 12/15-lipoxygenase activity. Importantly, PD1
treatment improved the survival and pathology of
severe influenza in mice, even under conditions
where known antiviral drugs fail to protect from
death. These results identify the endogenous lipid
mediator PD1 as an innate suppressor of influenza
virus replication that protects against lethal influenza
virus infection.112 Cell 153, 112–125, March 28, 2013 ª2013 Elsevier Inc.INTRODUCTION
Despite immunization programs, influenza A viruses are a major
cause ofmorbidity andmortality throughout theworld, especially
among individuals with high risk factors, such as diabetes,
asthma, or pregnancy (Clark and Lynch, 2011). Highly patho-
genic avian H5N1 influenza viruses continue to circulate with
mortality rates of up to 60% of infected patients (Beigel et al.,
2005). Influenza strains have also recently emerged that exhibit
resistance to antiviral drugs such as oseltamivir (Shankaran
and Bearman, 2012). Recently, a virus with its hemagglutinin
(HA) derived from H5N1 was identified that is transmissible in
ferrets, further supporting that H5N1 viruses have pandemic
potential (Imai and Kawaoka, 2012). Moreover, currently used
antiviral drugs, though beneficial if administered early in the
disease (Kumar, 2011), are not effective in critically ill patients
after influenza virus infections (Beigel et al., 2005; Clark and
Lynch, 2011; Kumar et al., 2010).
Influenza A viruses are negative-sense RNA viruses that
exploit the host cellular machinery for multiple phases of their
life cycle (Neumann et al., 2004). Recent genome-wide RNAi
screens have identified several host genes and molecular
networks crucial for influenza virus replication (Karlas et al.,
2010; Hao et al., 2008; Ko¨nig et al., 2010; Shapira et al., 2009).
However, whether bioactive lipid mediators and lipid metabolic
pathways might be involved in influenza virus infections is
unknown. Omega-3 polyunsaturated fatty acids (PUFA), such
as docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA), both of which are enriched in fish oils, serve as substrates
for the production of potent bioactive anti-inflammatory lipid
mediators, such as resolvins, protectins, maresins, and their
biosynthetic intermediates (Serhan, 2007; Serhan et al., 2012).
Here, we report that the DHA-derived protectin D1 isomer
(PD1; 10S, 17S-dihydroxydocosahexaenoic acid) markedly
attenuates influenza virus replication via interference with the
virus RNA nuclear export machinery. PD1 was identified in
self-limited resolving inflammatory exudates in vivo (Serhan
et al., 2002), where it regulates the innate local response and
stimulates resolution. Production of PD1 was downregulated
during severe influenza virus infections, e.g., with H5N1 avian
influenza viruses, and inversely correlated with the pathogenicity
of different H5N1 virus isolates. Importantly, PD1 treatment
improved the survival of influenza-virus-infected mice even at
later stages of the disease, when current antiviral therapies are
not effective (Arya et al., 2010), suggesting that PD1 could be
a novel therapeutic target for the treatment of severe influenza
virus infections.
RESULTS
The PUFA-Derived Mediator Protectin D1 Reduces
Influenza Virus Replication
To investigate the potential role of lipid metabolites in influenza
infections, we performed a screen of PUFA-derived lipids in
human lung epithelial (A549) cells infected with the influenza A
virus stain A/Puerto Rico/8/34 (H1N1) (PR8 virus) by using bioac-
tive lipid libraries that include prostaglandins (PGs), resolvins,
protectins, and other PUFA-derived metabolites (Figure 1A).
PR8-infected cells (multiplicity of infection [MOI]: 0.2) were
treated with PUFA-derived metabolites (1 mM each) and influ-
enza virus nucleoprotein (NP) mRNA expression was quantified
at 8 hr after infection (Figure 1A). Compared with vehicle treat-
ment, the arachidonic acid (AA)-derived products 12-HETE and
15-HETE, as well as the DHA-derived 17HDoHE and PD1, in-
hibited the expression of NP mRNA by more than 30%. Of
note, some compounds, e.g., 8,9-DHET, resulted in increased
NP mRNA levels that required further analysis; here, we focus
on compounds that can inhibit virus replication because they
may represent potential therapeutic targets for influenza
virus infection. Immunohistochemistry demonstrated that PD1,
17-HDoHE, 12-HETE, and 15-HETE administration markedly
decreased the numbers of cells that were positive for the influ-
enza virus NP protein and viral antigen R309 (Figure 1B). In
addition, PR8 virus titers were markedly decreased by the treat-
ment with 12-HETE, 15-HETE, 17HDoHE, and PD1 (Figure 1C).
Consistent with the results of our screen, the DHA-derived resol-
vins RvD1 and RvD2 showed no apparent inhibition (Figures 1B
and 1C). Because PD1 treatment among all bioactive mediators
tested led to the most potent inhibition of PR8 virus replication,
we focused on PD1 for our subsequent studies. We confirmed
that PD1 treatment attenuated influenza virus replication, as
assessed by NP protein production in PR8-virus-infected A549cells (Figure S1A available online). NP mRNA expression was
inhibited by PD1 treatment in a dose-dependent fashion (Fig-
ure S1B). Importantly, PD1 treatment also attenuated the
replication of highly pathogenic H5N1 influenza viruses, as as-
sessed by markedly reduced viral M protein mRNA expression
(Figures 1D and S1C), and decreased virus titers (Figures 1E
and S1D) in A549 and MDCK cells. Thus, our screen for PUFA-
derived metabolites identified PD1 as a suppressor of influenza
virus replication in cultured cells.
Reduction of Endogenous PD1 Production in Lungs of
Mice in Severe Influenza Virus Infection
To examine the metabolic profiles of PUFA-derived metabolites
in severe influenza infection in vivo, we conducted amediator lip-
idomics for AA-, DHA- and EPA-derived metabolites in lung
tissues obtained from wild-type mice subjected to intratracheal
PR8-virus infections (Ichikawa et al., 2013). All PR8-infected
animals died within 8 days (Figure S2A). NP mRNA expression
(Figure S2B) and virus titers (Figure S2C) rapidly increased after
infection peaking on day 2. PR8 infections also resulted in
markedly impaired pulmonary functions as assessed by tissue
resistance and tissue elastance (Figure S2D) (Sly et al., 2003).
Histologically, numbers of inflammatory cells were slightly in-
creased in the PR8-infected lungs on day 2, and on day 5 we
observed pulmonary edema, hemorrhage, and hyaline mem-
brane formation (Figure S2E). Thus, in line with previous reports
(Smith et al., 2011; Ichikawa et al., 2013), intratracheal infection
with PR8 influenza viruses induces lung pathologies that closely
mimic the symptoms of severe influenza in humans.
To identify the endogenous lipid mediators and pathway
metabolites during PR8 infections, lung tissues were obtained
from PR8- and mock-infected mice at 6, 12, 24, and 48 hr
after infection and subjected to liquid chromatography-tandem
mass spectrometry (LC-MS/MS)-based lipidomics analysis.
This technology has been recently developed and allows
researchers to identify and quantify more than 250 PUFA-
derived endogenous lipid mediators and pathway metabolites
including prostaglandins (PGs), leukotrienes (LTs), lipoxins
(LXs), resolvins, protectins, and other AA-, EPA-, DHA-derived
products (Arita, 2012). As shown in Tables S1, S2, and S3,
several lipid mediators were detectable in noninfected lungs
under baseline control conditions. In particular, cyclooxygenase
(COX) pathway products such as PGE2 and 6-keto PGF1a and
the 12/15-lipoxygenase (12/15-LOX) pathway metabolites 12-
HETE, 15-HETE, and 14-HDoHE were present in the lung tissues
of untreated control mice (Tables S1 and S2). Next, we examined
the relative ratios of AA-derived (Figure 2A), DHA-derived (Fig-
ure 2B), and EPA-derived (Figure 2C) metabolites in PR8-in-
fected versus control lungs. Intriguingly, among all the identified
mediators and metabolites, endogenous production of AA-
derived 12-HETE and 15-HETE, as well as DHA-derived 17-
HDoHE and PD1, showed the greatest level of reduction during
the course of the PR8 influenza virus infection (Figures 2A–2C);
these are the same series of lipid mediators that showed the
largest impact on influenza replication in A549 cells (Figure 1).
Akin to its effects on viral replication in cell culture, PD1 was
one of the most reduced lipid mediator in the lungs of PR8-in-
fected mice (Figure 2B).Cell 153, 112–125, March 28, 2013 ª2013 Elsevier Inc. 113
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Figure 1. Identification of PUFA-Derived Products Involved in Influenza Virus Replication
(A) Lipid library screening for influenza replication. A549 cells were infectedwith influenza PR8 virus (MOI: 0.2) and treatedwith PUFA-derived compound (1 mM) or
vehicle immediately after infection. Virus NP mRNA expression was analyzed by calculating the relative ratio of the indicated AA-, DHA-, and EPA-derived
compounds to vehicle treatment. Averages from three independent screens shown.
(B) Immunocytochemistry of influenza virus nucleoprotein (NP) and virus antigen R309. PR8-virus-infected A549 cells (MOI: 0.2) were treated with the indicated
compounds (1 mM each) or vehicle. Infected cells were fixed after a 24 hr postinfection and stained for NP (green) and virus antigen R309 (red). Nuclei (blue) were
counterstained with DAPI.
(legend continued on next page)
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To extend our results to other influenza virus strains, we intra-
nasally (i.n.) infected wild-type mice with 2009 H1N1 virus, avian
H5N1 (H5N1) virus, avian H5N1 virus carrying an attenuating Glu
mutation at position 627 of PB2 (H5N1 PB2-627E), or mock in-
fected them. Virus titers were higher in the lungs of mice infected
with the avian H5N1 virus as compared to 2009 H1N1 or H5N1-
PB2-627E-virus-infected mice (Figure S2F), confirming previous
results (Shinya et al., 2004). Lung tissues were obtained at 24
and 48 hr after infection and subjected to LC-MS/MS-based lip-
idomics analysis. Again, endogenous production of AA-derived
12-HETE and 15-HETE, and of DHA-derived 17-HDoHE and
PD1, was markedly downregulated in lungs infected with the
highly pathogenic avian H5N1 virus at both time points analyzed
(Figure 3). PD1 production was the most suppressed in H5N1-
virus-infected lungs, whereas it was even elevated in lungs in-
fected with the less pathogenic 2009 H1N1 virus and H5N1
PB2-627E virus strains (Figure 3), suggesting that endogenous
PD1 levels inversely correlate with the pathogenicity of influenza
virus strains. Taken together, our data show that endogenous
production of PD1 is markedly suppressed in the lungs of mice
intratracheally infected with PR8 virus or nasally infected with
the highly pathogenic avian H5N1 influenza virus.
PD1 Protects against Severe Influenza In Vivo
We next tested whether the PUFA-derived 12-HETE, 15-HETE,
17-HDoHE, and PD1, all of which attenuated virus replication
in cultured cells (Figure 1), could also protect against severe
influenza in mice. Mice were infected intratracheally with PR8
virus (1,500 TCID50); lipids mediators (1 mg/mouse) or vehicle
were given intravenously (i.v.) 12 hr before and immediately after
the PR8 virus infection. The lipids metabolites were given intra-
venously because they are autacoids and, as such, are rapidly
metabolized and inactivated in vivo. Consistent with our in vitro
data, PD1 treatment improved the survival of PR8-infected
mice (Figure 4A). To extend our results to a human pathogenic
virus isolate, we tested whether PD1 treatment could also affect
the survival ofmice infectedwith the 2009H1N1 virus.WhenPD1
was given i.v. 12 hr before and immediately after 2009 H1N1
virus infections, the survival of the virus-infected mice improved
(Figure 4B). We then tested whether the protective actions of
PD1 resulted from its anti-inflammatory functions in macro-
phages and neutrophils (Schwab et al., 2007). However, macro-
phage and neutrophil numbers in bronchioalveolar lavage (BAL)
fluid were seemingly unaffected by PD1 treatment in the lungs
of PR8 influenza-virus-infected mice (Figure S3A), although
the PD1-treated lungs did show slightly improved histological
changes at 2 days after infection (Figure S3B). Furthermore,
PD1 treatment did not significantly decrease the levels of the
proinflammatory cytokines IL-6, IP-10, and CXCL2 nor mRNA
expression (IL-6, IFN-b, CXCL1, and CXCL2) in the lungs on
days 2 and 5 after PR8 infection (Figures 4C and S3C). In
contrast, virus NPmRNA expression (Figure 4D), virus titers (Fig-(C) Virus titers. PR8-virus-infected A549 cells (MOI: 5) were treated with the indicat
at 24 hr after infection by focus forming unit (FFU) replication assay. **p < 0.01, *
(D and E) Effects of PD1 on H5N1 virus replication. H5N1 influenza-virus-infected
after infection. Viral M protein mRNA expression (D) and virus titers (E) were quan
with vehicle. Data in (C)–(E) are presented as means ± S.E.M. See also Figure S1ure 4E), and the number of virus antigen-positive cells (Figure 4F)
were all significantly reduced in the lungs of PD1-treated mice,
indicating that PD1 acts on viral replication.
Similar to our in vitro data (Figure 1), intravenous treatment
(1 mg/mouse) with RvD1 or RvD2 at 12 hr before and immediately
after PR8 virus infection had no apparent effect on the survival of
PR8-virus-infected mice (Figure 4G). Because LXA4 showed
a mild inhibition of virus replication (Figure 1) and LXA4 produc-
tion was suppressed during the course of severe influenza (Fig-
ure 2A), we also tested the effect of LXA4 on the survival of mice
infected with PR8 influenza virus in vivo. However, treatment
(1 mg/mouse, i.v.) with LXA4 also had no apparent effect on the
survival of PR8-virus-infected mice (Figure 4G). Given that
RvD1, RvD2, and LXA4 are known to have anti-inflammatory
properties (Serhan and Levy, 2003), we next asked whether
they could decrease the inflammatory cytokine production initi-
ated in response to virus infection. However, RvD1, RvD2, or
LXA4 treatment did not decrease the proinflammatory cytokine
levels (IL-6, IP-10, CXCL2) in the lungs on days 2 and 5 after
PR8 infection (Figure S3D). In addition, virus replication, as
assessed by NP mRNA, was apparently not affected following
treatment with these lipid metabolites (Figure 4H).
We finally examined whether PD1 treatment has a therapeutic
benefit after the infection was established.Mice were infected i.t.
with PR8 virus and treated with PD1 (100 ng/mouse; i.t.) or
vehicle 2 days after the initial infection; infected mice were
then mechanically ventilated, mimicking the therapeutic setting
for critically ill influenza patients in intensive care units. We chose
the 48 hr time point because currently available anti-influenza
drugs are thought to be beneficial if administered early after
infection but ineffective if administered around 48 hr after infec-
tion (Kumar, 2011). Intriguingly, such therapeutic PD1 treatment
significantly improved the pulmonary functions of PR8-infected
mice as assessed by tissue resistance (Figure 4I) and tissue ela-
stance (Figure 4J). A similar administration regiment using RvD1
or RvD2 did not improve pulmonary functions (Figures S3E and
S3F). Importantly, when mice were treated with the antiviral
drug peramivir (Arya et al., 2010) or PD1 alone at 48 hr postinfec-
tion, 70%–75%of the animals still diedwithin 16 days (Figure 4K).
However, PD1 plus peramivir treatment beginning 48 hr after
infection completely rescued the mice from death due to the
influenza infection (Figure 4K). Of note, if treated with peramivir
immediately after infection, all animals survived (Figure S3G).
These results show that PD1 has a marked beneficial effect on
severe influenza virus infections both prophylactically and,
most importantly, therapeutically in vivo.
PD1 Inhibits Nuclear Export of Viral Transcripts
Next, we explore the mechanisms by which PD1 inhibits
influenza virus replication. Consistent with our in vivo data
(Figures 4C, and S3C), expression of antiviral (IFNb) or anti-
inflammatory (IL-8) cytokines was unaffected by PD1 treatmented compounds (8 mMeach) or vehicle. Infectious virus particles were quantified
p < 0.05 compared with vehicle.
A549 cells (MOI: 0.02, 0.2) were treated with PD1 (8 mM) or vehicle immediately
tified at 24 hr after infection by qRT-PCR and FFU assay. **p < 0.01 compared
.
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Figure 2. Mediator Lipidomics in Severe Influenza in Mice
(A–C) Lung tissues were obtained from intratracheally PR8 virus (1 3 104 TCID50)- or mock (PBS)-infected mice at 0, 6, 12, 24, and 48 hr after infection and
subjected to LC-MS/MS lipidomics analysis. Changes in the production of PR8-virus-infected lungs (Flu) relative to PBS-treated controls (PBS) are shown for (A)
AA-, (B) DHA-, and (C) EPA-derived metabolites at 0, 6, 12, 24, and 48 hr after infection. n = 5 per each group. See also Figure S2, Tables S1, S2, and S3.of influenza-virus-infected A549 cells (Figure S4A), suggesting
that PD1 is unlikely to attenuate influenza virus replication
through its possible antiviral or anti-inflammatory responses.116 Cell 153, 112–125, March 28, 2013 ª2013 Elsevier Inc.Thus, we wondered whether PD1 could affect influenza virus
replication via controlling virus life cycle. The influenza viral
genome consists of negative-sense RNA (vRNA) packaged in
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Figure 3. Mediator Lipidomics in H5N1
Influenza Virus Infection in Mice
WT mice were intranasally infected with 2009
H1N1 virus (2009 H1N1), avian H5N1 virus (H5N1),
H5N1 virus with an attenuating mutation of Glu at
position 627 of PB2 (H5N1 PB2-627E), or mock
infected with PBS as a control. Lung tissues were
obtained from mice at 24 and 48 hr after infec-
tion and subjected to lipidomics analysis. Red
columns indicate percent increases and blue
columns percent decreases of the indicated lipid
mediators in influenza virus (2009 H1N1, H5N1,
H5N1 PB2-627E)-infected lungs as compared to
PBS-treated controls. Grey columns indicate that
the products were not detectable. n = 3 per group.viral ribonucleoprotein (vRNP) complexes. vRNA is replicated
into cRNA, which serves as the template for vRNA neosynthesis.
After the formation of vRNPs in the nucleus, vRNAs are exported
to the cytoplasm (Neumann et al., 2004). In addition, an initial
round of transcription produces 50 capped and 30 poly(A) viral
mRNA that is also exported to the cytoplasm. To examine
whether PD1 affects the nuclear export of influenza virus RNA,
we visualized the localization of PR8 virus segment 7 mRNA
and vRNA in infected A549 cells using fluorescence in situ
hybridization (FISH). Upon PR8 virus infection, virus mRNA and
vRNAwere primarily localized in the nucleus at 5 hr after infection
but shifted to the cytoplasm at 8 hr in the vehicle-treated cells
(Figure 5A). PD1 treatment markedly attenuated cytoplasmicCell 153, 112–12translocation of virus mRNA and vRNA
(Figure 5A). Of note, RvD1 treatment did
not affect the export of viral RNAs (Fig-
ure 5A). As a consequence, virus mRNA
and vRNA expression was significantly
reduced in the PD1-treated but not
RvD1-treated cytoplasmic fraction 8 hr
after PR8 infections (Figure 5B). Thus,
our data indicate that PD1 inhibits nuclear
export of influenza virus RNAs.
Genome-wide RNAi screens for host
factors implicated in influenza virus repli-
cation identified a critical role for the
mRNA transporter NXF1 (also known as
Tap) (Karlas et al., 2010; Hao et al.,
2008), although the precise mechanisms
remained unknown. We therefore as-
sessed a potential involvement of NXF1
in the PD1-regulated nuclear export of
influenza virus RNA. Indeed, knockdown
of NXF1 in A549 cells (Figure S4B), but
not of the related transporters p15/NXT1
(Herold et al., 2001), NXT2, or CRM1/
XPO1 (Stade et al., 1997), significantly
attenuated PR8 influenza virus replication
as assessed by NP mRNA expression
(Figure 5C), NP protein levels (Fig-
ure S4C), and virus titers (Figure S4D).
Consistent with a previous report (Readand Digard, 2010), FISH analyses further confirmed that knock-
down of NXF1 inhibited the nuclear export of virus mRNA and
vRNA (Figure S4E). Of note, although knockdown of p15/NXT1
or its homolog NXT2 (Herold et al., 2000) alone did not attenuate
virus replication, knockdown of both p15/NXT1 and NXT2 atten-
uated the influenza virus replication (Figure 5C). Knockdown of
CRM1/XPO1 did not affect the nuclear export of influenza virus
transcripts (Figure S4F). NXF1 forms a functional heterodimer
with the p15/NXT1 protein (Gru¨ter et al., 1998; Herold et al.,
2000; Katahira et al., 1999; Rodrı´guez-Navarro and Hurt, 2011).
NXF1 proteins, via their middle (M) and C-terminal domains (Fig-
ure S4G), bind to phenylalanine-glycine (FG) repeat-containing
nucleoporins (Nups) that line the nuclear pore channel (Ho5, March 28, 2013 ª2013 Elsevier Inc. 117
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Figure 4. Protective Role of PD1 against Influenza Virus Infection In Vivo
(A) Survival of influenza-virus-infected WT mice upon treatment with PUFA-derived metabolies. n = 7 for vehicle, n = 7 for 12-HETE, n = 8 for 15-HETE, n = 8 for
17-HDoHE, and n = 8 for PD1 group. **p < 0.01 compared with vehicle.
(B) Survival of WTmice intratracheally infected with 2009 H1N1 virus upon treatment with PD1 (1 mg/mouse) (n = 6) or vehicle (n = 6). PD1 treatment improved the
survival of virus-infected mice (p = 0.03).
(C–F) Effects of PD1 on host cytokine levels and viral replication. Cytokine (IL-6, IP-10, and CXCL2) levels in lungs at 2 and 5 days postinfection are shown (C). NP
mRNA expression (D) and virus titers (E) were measured in lung 24 hr postinfection. n = 5 per each group. n.s., not significant. **p < 0.01 compared with vehicle.
(F) Lung tissues at 2 days after infection were stained with the R309 antibody to detect influenza virus antigen.
(legend continued on next page)
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et al., 2002; Liker et al., 2000). FG-Nups facilitate RNA transport
as their repeats provide docking sites for carriers during their
movement across the nuclear pore complex (Reed and Hurt,
2002; Stewart, 2010). Among FG-Nups, knockdown of Nup62,
but not Nup98 or Nup214, significantly attenuated virus replica-
tion assessed by NP mRNA expression (Figure 5D) and virus
titers (Figure S5A) in A549 cells, as previously reported for immu-
nodeficiency virus type 1 (HIV-1) infections (Monette et al., 2011).
FISH analyses further showed that Nup62 knockdown inhibited
the nuclear export of virus mRNA and vRNA (Figure S5B),
whereas knockdown of Nup98 nor Nup214 did not affect the
nuclear export of influenza virus transcripts (Figure S5C).
Whether influenza virus RNAs can directly bind NXF1 has been
elusive. By using a cell-free in vitro RNA gel shift assay, we found
that recombinant protein expressing full-length NXF1 1-619 and
p15/NXT1 (NXF1-p15) generated band shifts of influenza virus
mRNA and vRNA (Figure S6A), indicating that influenza virus
RNAs directly binds to NXF1-p15. In contrast, we failed to detect
a direct binding of Nup62-FG protein to virus RNAs (Figure S6B).
Interestingly, coincubation of the NXF1-p15 and Nup62-FG
proteins generated a supershift of influenza virus mRNA and
vRNA (Figure 5E), supporting the notion that NXF1-p15 and
Nup62-FG form a protein complex in vitro, which can bind virus
RNAs. Of note, immunoprecipitation experiments showed that
Nup62 indeed associated with NXF1 in noninfected and infected
cells (Figure S6C). These data indicate that influenza virus RNAs
directly bind to NXF1 and that NXF1, in cooperating with a key
docking protein Nup62, facilitates influenza virus RNAs export
and virus replication.
We next tested whether PD1 could interfere with the recruit-
ment of virus RNAs to NXF1 that can bind Nup62 using an
RNA immunoprecipitation (RIP) assays. PD1, but not RvD1,
treatment significantly reduced the amount of virus mRNA and
vRNA that immunoprecipitated with the anti-NXF1 antibody
(Ab) (Figure 5F). The Ab used was immunoprecipitated with
NXF1 (Figure S6D). To further confirm this finding, we conducted
a RIP sequencing (RIPseq) analysis. The RNAs that immunopre-
cipitated with the anti-NXF1 Ab indeedmapped to influenza virus
RNAs. PD1 treatment significantly reduced the copy number of
all influenza virus RNAs that immunoprecipitated with the anti-
NXF1 Ab (Figure 5G). Furthermore, we detected the presence
of Nup62 microclusters around the nuclear rim and a distinct
speckled cytoplasmic staining at 8 hr after infection (Figure 5H).
Importantly, upon PD1, but not RvD1, treatment, Nup62 re-
mained at the nuclear envelop in the virus-infected cells (Fig-
ure 5H). Taken together, our data indicate that PD1 inhibits the
recruitment of virus RNAs to NXF1 that can cooperate with(G andH) RvD1, RvD2, LXA4, or vehicle was given i.v. 12 hr before and immediately
(G). NP mRNA expression was measured in lungs at 2 and 5 days postinfection
(I and J) Therapeutic effects of PD1 on lung function of PR8-infectedmice. Two da
thenmechanically ventilated for 2.5 hr. Changes in pulmonary tissue resistance (I)
time course compared with vehicle treatment.
(K) Survival of influenza-virus-infected mice upon delayed treatment with the ant
(n = 7). WT mice were infected intratracheally with PR8 virus. In the peramivir gro
from 2 days postinfection PD1 (1 mg/mouse/day) was given i.v. for 3 consecutiv
at 2 days postinfection and PD1 (1 mg/mouse/day) was given i.v. for three conse
Data in (C), (D), (E), and (H)–(J) are presented as means ± S.E.M. See also FigureNup62 for RNA export, thereby attenuating virus RNA export
and replication.
Finally, we asked whether PD1 also affects nuclear export of
host poly(A) mRNA. FISH analysis showed that PD1 treatment
had no apparent impact on the nuclear export of host bulk
poly(A) mRNA in the influenza-virus-infected cells (Figure 5I).
To confirm this finding, we isolated nuclear and cytoplasmic
RNA fractions from the cells at 8 hr after mock or PR8 virus
infection and subjected to RNA sequencing (RNAseq) analysis.
Consistent with our FISH data (Figure 5I), the distributions of
nuclear and cytoplasmic RNA sequences were largely unaf-
fected by PD1 treatment (Figure 5J), although some RNAs
appeared changed following PD1 treatment (Table S4); the
significance of these changes needs to be determined, though
none of these changed RNA have been yet implicated in virus
replication.
PD1 Production Is 12/15-LOX Dependent
12/15-LOX (the murine ortholog of human 15-LOX1) (Chanez
et al., 2002) is known to be a key enzyme in the biosynthesis of
PD1 (Yamada et al., 2011). To test whether the generation of
PD1 in the influenza-virus-infected lung was indeed dependent
on 12/15-LOX, we conducted lipidomics for PUFA-derived
metabolites in 12/15-LOX knockout (KO) (Sun and Funk, 1996)
versus control wild-type (WT) mice. Compared with WT mice,
levels of PD1 were reduced in 12/15 LOX KO mice at baseline
(Figure 6A). Upon influenza virus infection for 24 hr, production
of PD1 wasmarkedly reduced in 12/15 LOX KOmice (Figure 6A).
In addition, the production of 17-HDoHE, the upstream product
of PD1, was also markedly reduced in 12/15 LOX KO mice at
baseline and at 24 hr postinfection (Figure 6A). Of note, produc-
tion of LXA4 was apparently not affected by the genetic inactiva-
tion of 12/15-LOX (Figure S7A). 5-lipoxygenase followed by
12-lipoxygenase action (Papayianni et al., 1995) might be
involved in the production of lipoxin A4. These data indicate
that the endogenous production of PD1 is critically dependent
on 12/15-LOX expression.
In lungs, 12/15-LOX is predominantly expressed in epithelial
cells and leukocytes (Chanez et al., 2002). In PR8-infected
mice, mRNA (Figure 6B) and protein levels (Figure 6C) of 12/
15-LOX were decreased in lungs. NP mRNA levels (Figure 6D)
and virus titers (Figure 6E) were significantly higher in the
lung tissues of PR8-virus-infected 12/15-LOX deficient mice at
2 days postinfection. 12/15-LOX KO mice also exhibited greater
body weight loss after PR8 virus infections (Figure 6F). Further-
more, we isolated mouse embryonic fibroblasts (MEFs) from
WT and 12/15-LOX KO mice and infected them with the PR8after PR8 infection ofWTmice (n = 6 for each group). Percent survival is shown
(H).
ys postinfection mice were intratracheally treated with PD1 or vehicle (veh), and
and tissue elastance (J) were analyzed. n = 6 per group. **p < 0.01 for the entire
iviral drug peramivir (n = 5), PD1 (n = 7), peramivir plus PD1 (n = 7), or vehicle
up, 2 days postinfection, peramivir (10 mg/kg) was given i.v. In the PD1 group,
e days. In the peramivir plus PD1 group, peramivir (10 mg/kg) was given i.v.
cutive days as indicated.
S3.
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Figure 5. PD1 Inhibits Nuclear Export of Viral Transcripts
(A andB) A549 cells were infectedwith influenza PR8 virus (MOI: 2) and treatedwith PD1 (2.7 mM) or vehicle immediately after infection. Infected cells were fixed at
the indicated time points, and PR8 virus mRNA and virus vRNA (A) were detected by fluorescence in situ hybridization. Nuclei were counterstained with DAPI.
Cytoplasmic and nuclear fractions were separately isolated from the cells at 8 hr after infection, and virus mRNA and vRNA (B) were quantified by qRT-PCR.
*p < 0.05 compared with vehicle.
(C and D) siRNA knockdown of RNA export genes (C) or FG-nucleoporins (D) in PR8 influenza-infected A549 cells (MOI: 0.2). NPmRNA expressionwas quantified
at 24 hr after infection by qRT-PCR. **p < 0.01 compared with control siRNA.
(legend continued on next page)
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viruses. NPmRNA levels (Figure 6G) and virus titers (Figure S7C)
were againmarkedly higher in 12/15-LOX KOMEFs. Importantly,
the elevated NP mRNA expression (Figure 6G) and virus titers
(Figure S7C) in the 12/15-LOX KOMEFs were significantly atten-
uated by the treatment with PD1, 17-HDoHE, or a combination of
both. These results show that the 12/15-LOX is the key enzyme
required for the biosynthesis of PD1 and 17-HDoHE in influenza-
virus-infected mouse lung.
DISCUSSION
Novel families of biologically active lipid mediators derived from
PUFA precursors have recently been uncovered and their com-
plete stereochemical assignments established (Schwab et al.,
2007; Serhan, 2007; Serhan et al., 2011; Isobe et al., 2012).
These lipid mediators include AA-derived lipoxin A4 (LXA4),
DHA-derived PD1 (also known neuroprotectin D1 when gener-
ated in neuronal tissues), D series resolvins (RvD1, RvD2), and
the EPA-derived E series resolvins (Serhan, 2007). These medi-
ators are known to have anti-inflammatory properties and
display potent protective actions in experimental inflammatory
diseases such as peritonitis (Schwab et al., 2007; Yamada
et al., 2011) and even Alzheimer’s disease (Lukiw et al., 2005).
Here, we used mediator lipidomics to show the metabolic
profiles and functions of these mediators in the pathology of
influenza virus infection. To examine whether such bioactive
mediators and biosynthetic intermediates are involved in influ-
enza virus replication, we screened PUFA-derived products for
their effects on influenza virus replication. Among them, PD1
markedly attenuated influenza virus replication and, most impor-
tantly, promoted survival of infected mice. Similar to PD1, RvD1
and RvD2 are DHA-derived products of the 12/15-LOX pathway
(Serhan, 2007). However, RvD1 and RvD2 were under the detec-
tion limit after PR8 or H5N1 virus infections, possibly because of
scarce infiltration with neutrophils.
The modes of interaction of NXF1 with cellular and viral RNAs
are likely to be different. Constitutive transport elements (CTE) of
retroviral RNAs can directly bind NXF1 (Braun et al., 1999; Gru¨ter
et al., 1998), and NXF1 has been shown to control ICP27-medi-
ated export of Herpes simplex virus (HSV)-1 mRNA (Yatherajam
et al., 2011). Although influenza virus infections have been shown
to downregulate the host mRNA export machinary by forming an
inhibitory complex consisting of viral NS1 and the host NXF1,
p15, and other mRNA export factors (Satterly et al., 2007), it
was unknown whether NXF1 is in fact involved in the virus RNA
export. We show that influenza virus RNAs directly bind to
NXF1 and that NXF1, in cooperating with Nup62, facilitates influ-(E) Coincubation of NXF1-p15 plus Nup62-FG proteins generated a supershift o
control.
(F and G) RNA immunoprecipitaion and viral RNA sequencing. Input and immunop
immunoprecipitated RNAs were subjected to RNA sequencing. Individual graph
(H) Immunocytochemistry for Nup62 (green) and NXF1 (red) expression in the PD
(I) The infected cells were fixed at the indicated time points, and Poly(A) mRNA w
with DAPI.
(J) Host mRNA sequencing. Nuclear and cytoplasmic fractions were isolated fro
subjected to RNA sequencing. Individual graphs represent the pairwise relations
treatment in nuclear (left) and cytoplasmic (right) RNAs under noninfected and in
Data in (B), (C), (D), and (F) are presented as means ± S.E.M. See also Figures Senza virus RNAs export from the nucleus to the cytoplasm.
However, to date it remains largely unknown the involvements
of viral proteins and/or adaptor proteins in the NXF1-mediated
influenza virus RNAs export (Schneider and Wolff, 2009). Impor-
tantly, we found that PD1 attenuates the recruitment of virus
RNAs to NXF1 that can bind Nup62 and suppresses the altered
localization of Nup62 in the virus-infected cells. The precise
mechanisms involved in this process including the PD1’s inter-
action to viral proteins such as NS1 should be clarified in the
future study. Furthermore, a yet unidentified specific receptor
for PD1would further raise the important question of how endog-
enous PD1 controls the downstream pathways connecting to
NXF1-Nup62, although PD1 could also have many yet unex-
plored effects beyond regulation of the nuclear pores.
A key approach to treat severe influenza has been pharmaco-
logical targeting of both the virus life cycle and the subsequent
extreme pulmonary inflammation. Current anti-influenza virus
drugs are beneficial only if administered early after infection;
they are much less effective if administered 48 hr after infection
(Kumar, 2011). In this context, a key finding of our study is that
treatment of PD1 beginning around 48 hr after the initial infection,
combined with peramivir, completely rescued mice from flu
mortality, indicating that PD1 has a marked beneficial effect
on severe PR8 influenza virus infections both prophylactically
and, most importantly, therapeutically. Deep RNA sequencing
showed that PD1 exhibits only minor effects on host poly(A)
mRNA nuclear export under both noninfected as well as infected
conditions, although it has not yet identified how PD1 inhibits
the export specific for virus RNA rather than host RNA. Antiviral
cytokine IFNb expression levels were also not affected by PD1
treatment in vivo and in vitro. These results may imply that PD1
treatment is not likely to induce a harmful inhibition of host
RNA export that could possibly produce detrimental side effects
in host cells. Given its demonstrated potency, its potent anti-
inflammatory properties in sterile and bacterial inflammation
(Serhan, 2007), and its production in healthy human airways
and reduction in disease (Levy et al., 2007), PD1 could serve
as a novel antiviral drug as well as a biomarker for severe and
lethal influenza virus infections.
EXPERIMENTAL PROCEDURES
Viruses
A/Puerto Rico/8/34 (H1N1; PR8), A/California/04/2009 H1N1 (2009 H1N1),
A/Vietnam/1203/04 H5N1 (H5N1), and a mutant H5N1 virus possessing
a single amino-acid substitution, from lysine to glutamic acid, at position 627
in PB2 (H5N1 PB2-627E) were used. BSL3 conditions were used for experi-
ments with H5N1 and H5N1 PB2-627E viruses.f influenza virus mRNA and vRNA. Virus RNA alone (N) served as a negative
recipitaed RNAs were analyzed by RT-qPCR for virusmRNA and vRNA (F). The
s represent the read depth Log10 (RPM) for each segment of the virus (G).
1-, RvD1-, or vehicle treated cells at 8 hr after infection.
as detected by fluorescence in situ hybridization. Nuclei were counterstained
m the cells at 8 hr after mock or PR8 virus infection and the extracted RNAs
hips of the expression level (FPKM) comparing PD1 (y axis) and vehicle (x axis)
fected conditions.
4, S5, S6, and Table S4.
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Figure 6. 12/15 LOX-Dependent PD1 Production in Influenza Virus-Infected Lungs
(A) Lipidomics for 12/15-LOX knockout (KO) mice. WT and 12/15-LOX KO mice were infected intratracheally with PR8 virus (1 3 104 TCID50). Lung
tissues were sampled at time point 0 (baseline) and 24 hr postinfection. The concentrations (pg/mg tissue) of the DHA-derived metabolites are shown; n = 5
per group.
(B) WT mice were intratracheally infected with mock (PBS) or PR8 virus. Lung tissues were sampled at the indicated time points postinfection and 12/15-LOX
mRNA levels measured by qRT-PCR. *p < 0.05 for the whole time course compared to PBS controls.
(C) Lung tissues were sampled from WT mice at the indicated time points postinfection, and used for western blotting using Abs to 12/15-LOX and b-actin as
a loading control. Lung tissues obtained from 12/15 LOX KO mice served as a negative control.
(legend continued on next page)
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Animals
C57BL/6micewere bred at our animal facility. 12/15-LOXdeficientmice on the
C57BL/6 background were purchased from the Jackson Laboratory. Animal
experiments and housing of mice were performed in accordance with institu-
tional guidelines.
Intratracheal Influenza Virus Infection Model and Measurements of
Respiratory Function
Mice were intratracheally infected with influenza viruses as described else-
where (Ichikawa et al., 2013). For respiratory function, airway elastance and
resistance were measure as described elsewhere (Imai et al., 2005, 2008)
using the flexiVent system (SCIREQ).
Mediator Lipidomics
LC-MS/MS-based lipidomics analyses were performed using an high-
performance liquid chromatography (HPLC) system (Waters UPLC) with
a linear ion trap quadrupole mass spectrometer (QTRAP5500; AB SCIEX)
equipped with an Acquity UPLC BEH C18 column (Waters) as described
(Arita, 2012). MS/MS analyses were conducted in negative ion mode, and
fatty acid metabolites were identified and quantified bymultiple reaction moni-
toring (MRM).
Lipid Metabolites
The Protectin D1 isomer (PD1, 10S,17S-diHDoHE), RvD1, RvD2, and 15-
HETE-d8, LTB4-d4, and PGE2-d4 were purchased from Cayman Chemical.
To screen for PUFA-derived compounds, we also used the Bio-active screen
Lipid II Library (Cayman Chemical).
Virus Infection of Cultured Cells
TheA549 human lung epithelial cells,mouse embryonic fibroblasts andMadin–
Darby canine kidney cells (MDCK) were washed with PBS and then infected
with virus at the indicated MOIs in DMEM 0.1% BSA for 1 hr at 37C. Cells
were then washed and incubated for the indicated time periods at 37C in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FCS.
Immunocytochemistry
A549 cells on glass coverslips were fixedwith 4%paraformaldehyde and incu-
bated with anti-NP Abs (ATCC, Hb65), anti-R309 Abs (Itoh et al., 2009), anti-
NXF1-C Abs (Katahira et al., 1999), or anti-Nup62 MAbs (BD Transduction
Laboratories), and then incubated with appropriate secondary antibodies.
Coverslips were mounted with mounting medium containing 4’,6-diamidino-
2-phenylindole (DAPI). Images were analyzed with a multiphoton laser micro-
scope (A1R MP, Nikon).
Fluorescent In Situ Hybridization
FISH for influenza virus RNAs and poly(A) mRNA was conducted as
described previously (Amorim et al., 2007). To generate a digoxigenin labeled
positive- or negative-sense RNA probe, we linearized pSPT19-PR8-M plasmid
and transcribed it in vitro with SP6 or T7 RNA polymerase, respectively, by
using DIG-RNA labeling kit (Roche). A Cy3-labeled oligo (dT) probe was
synthesized for poly(A) mRNA FISH. A549 cells were fixed and permeabilized.
After 1 hr prehybridization, the cells were hybridized with the RNA probe for
16 hr at 37C. A digoxigenin labeled probe was detected by indirect
immunofluorescence with an antidigoxigenin fluorescein Fab fragment
(Roche). Images were analyzed using multiphoton laser microscopy (A1R
MP, Nikon).(D and E) WT and 12/15-LOX KOmice were infected intratracheally with PR8 virus
tissues at 24 hr postinfection by qRT-PCR and focus forming unit (FFU) replicati
(F) Body weight changes in influenza-infected 12/15-LOX KO mice. WT (n = 10)
(10 TCID50).
(G) Mouse embryonic fibroblasts (MEFs), obtained fromWT or 12/15-LOX KOmic
(8 mM), or a combination of both (4 mM each) immediately after infection. Virus N
**p < 0.01. *p < 0.05. Data in (A), (B), (D), (E), (F),and (G) are presented as meansCellular Fractionation
Cytoplasmic and nuclear fractions of the cells were segregated by use of
a subcellular protein fractionation kit (Thermo Scientific) in the presence of
protease inhibitor cocktail (Roche) and RNase inhibitor (Toyobo).
Quantitative Real-Time PCR
RNA was extracted from cells using the RNeasy Mini Kit (QIAGEN, Valencia,
CA). First-strand cDNA was synthesized from DNA-free RNA using a Prime-
script RT reagent kit (Takara). Samples of first strand cDNA were subjected
to real-time PCR quantification (Takara) using specific primers for the indi-
cated RNAs with GAPDH or 18S as an internal control. Relative amounts of
RNAs were calculated by using the comparative CT method.
RNA-Binding Protein Immunoprecipitation Assay and RIP
Sequencing
RIP was carried out using an immunoprecipitation kit (RIP-assay kit; MBL).
Briefly, cells were homogenized and incubated overnight with protein G
agarose beads (Thermo) preincubated with an anti-NXF1 Ab (BD Biosciences)
or control Ab. RNAs bound to the beads were purified, and qPCR analysis was
carried out. For RIP sequencing, immunoprecipitated RNAs were subjected to
RNA sequencing analysis using HiSeq2000 (Illumina). The sequencing run
yielded 30 million reads on average for the PD1 and vehicle treatment
samples. Low-quality bases in sequencing reads were trimmed, and the
trimmed reads were mapped to the influenza genome of the strain A/Puerto
Rico/8/34(H1N1) by using Bowtie2 (Langmead and Salzberg, 2012). Read
counts were normalized to reads per million reads (RPM).
RNAseq
Nuclear and cytoplasmic fractionated RNAs were subjected to RNA
sequencing analysis using HiSeq2000 (Illumina). The sequencing run yielded
12 million reads on average. The quality-filtered reads were aligned to the
human genome hg19 by using TopHat (Trapnell et al., 2009). The relative
expression levels (fragments per kilobase per million mapped fragments,
FPKM) were calculated using cuffdiff within the software package Cufflinks
version 2.0.2 (Trapnell et al., 2010). The software package CummeRbund
version 2.0.0 was used to analyze the output data of cuffdiff (Trapnell et al.,
2012).
In Vitro RNA-Binding Assay
To generate PR8Mpositive-sensemRNAand negative-sense vRNA, linearized
pSPT19-PR8-Mwas in vitro transcribedwith SP6RNApolymerase and T7RNA
polymerase, respectively, by using MEGAscript kit (Ambion), followed by bio-
tinylation using an RNA30 end biotinylation kit (Pierce). In vitro RNA gel shift
assayswerecarriedout usingachemiluminescentRNAelectrophoreticmobility
gel shift assay (EMSA) kit (Thermo Scientific) following the manufacturer’s
instructions. RNA-protein complexes were separated by 4% native polyacryl-
amide gel, electroblotted to hybond N+ membrane, and the bands visualized
with streptavidin-horseradish peroxidase conjugate and chemiluminescence.
Statistical Analyses
Measurements at single time points were analyzed by using an unpaired t test
or analysis of variance (ANOVA). Time courses were analyzed by repeated
measurements (mixed model) of ANOVA. Log-rank tests were performed on
Kaplan-Meier survival curves. All statistical tests were calculated using the
GraphPad Prism 5.00 program. p < 0.05 was considered to indicate statistical
significance.(13 104 TCID50) Virus NP mRNA (D) and virus titers (E) were quantified in lung
on assay. n = 5 per each group. *p < 0.05 compared with WT.
and 12/15-LOX KO (n = 11) mice were infected intratracheally with PR8 virus
e, were infected with PR8 virus (MOI: 2) and treated with PD1 (8 mM), 17-HDoHE
P mRNA expression was quantified in the infected cells at 24 hr postinfection.
± S.E.M. See also Figure S7.
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